Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
Good day, Sunshine: Tools help docs track payments
With a new era of transparency for doctors and life science manufacturers kicking off today, here’s how some organizations are keeping physicians informed.
Industry pushing for further clarity on Sunshine Act
With a clear buffet exemption in-hand, the agency’s position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
The drug maker asked CMS to approve its Amyvid PET tracer for Medicare beneficiaries, but CMS declined, saying in a draft decision that widespread use would be of little value.
A BMJ study finds that medical school gift bans make doctors less likely to prescribe a new drug. Also of note: consumers think money motivates some doctors’ recommendations.